Transdermal estradiol spray in Nordic menopausal women: real-world patient outcomes

This study aimed to evaluate the impact of transdermal estrogen therapy on health-related quality of life (HRQoL) and treatment tolerability in postmenopausal women in a real-world setting.
A prospective, non-interventional study was conducted in Sweden and Finland. Participants used a spray delivering 1.53 mg of estradiol (E2) per 90 µl dose. HRQoL (measured using the Menopause Rating Scale [MRS]), dosing patterns and treatment satisfaction were assessed through web-based questionnaires at baseline, week 6 and week 12. Mixed-model repeated-measures analysis was performed.
Of 249 participants (mean age 52.1 years), 165 (66.3%) completed the 12-week follow-up. Most women (67.2%) used one or two sprays daily. The mean MRS total score was 17.8 at baseline, and decreased by 8.6 points at week 6 (p = 0.012) and 9.9 points by week 12 (p < 0.0001). Improvements were seen across all MRS domain scores (somatovegetative, psychological and urogenital), including hot flashes, sleep issues, depressive moods and sexual problems. Most participants reported satisfaction (78.8%), ease of use (95.2%) and willingness to recommend the spray to a friend (84.2%). No related adverse reactions were reported.
The E2 spray improved HRQoL and was well tolerated. Flexible dosing, ease of use and real-world effectiveness support that the spray is a practical, user-friendly treatment for menopausal symptoms.
In this study, 249 women in Sweden and Finland used a transdermal spray that delivers estradiol, a type of estrogen, through the skin. Participants completed online surveys at the start of the study and again at 6 and 12 weeks, using the Menopause Rating Scale to assess overall well-being.
Most women applied one to two sprays per day on one arm. Over the course of the study, they experienced substantial improvement. By week 12, the average symptom score had decreased by half, which was a clinically meaningful change. Symptoms such as hot flashes, night sweats, sleep disturbances, low mood and sexual problems improved over time. The spray was well tolerated, and most participants found it easy to use. Nearly 80% reported being satisfied with the treatment, and more than 84% said they would recommend it to a friend.
Overall, the estradiol spray effectively reduced menopausal symptoms and improved daily functioning for most participants. Its proven effectiveness, ease of use and flexible dosing make estradiol spray a practical option for day-to-day management of menopausal symptoms.